Erasca, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Erasca completed an upsized July 2026 public offering raising $632.5M gross proceeds (plus $258.8M from January 2026 offering), strengthening cash position to $384.3M as of June 30, 2026. ERAS-0015 demonstrated 57% uORR at 8 weeks in 2L+ KRAS G12X pancreatic cancer with favorable tolerability; company plans three potentially registration-enabling trials in pancreatic and lung cancers, with Phase 1 expansion and combination data expected H1 2027, and Phase 3 pivots initiating 2027–2028. Q2 2026 R&D expenses were $35.9M (vs. $21.2M YoY); net loss was $44.1M ($0.14/share).
Why this rating
Large capital raise (>200% of market cap) materially extends runway and funds pivotal trials; early ERAS-0015 efficacy (57% ORR) is clinically encouraging. Offset by elevated burn rate ($35.9M R&D/quarter, 70% YoY increase) and clinical-stage risk; no approved products. Meaningful for trajectory but execution risk remains.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.